Mechanism of action and therapeutic potential of dimethyl fumarate in ischemic stroke

Abstract

Dimethyl fumarate (DMF) is an immunomodulatory drug currently approved for the treatment of multiple sclerosis and psoriasis. Its benefits on ischemic stroke outcomes have recently come to attention. To date, only tissue plasminogen activators (tPAs) and clot retrieval methods have been approved by the FDA for the treatment of ischemic stroke. Ischemic conditions lead to inflammation through diverse mechanisms, and recanalization can worsen the state. DMF and the nuclear factor erythroid-derived 2-related factor 2 (Nrf2) pathway it regulates seem to be important in postischemic inflammation, and animal studies have demonstrated that the drug improves overall stroke outcomes. Although the exact mechanism is still unknown, studies indicate that these beneficial impacts are due to the modulation of immune responses, bloodbrain barrier permeability, and hemodynamic adjustments. One major component evaluated before, during, and after tPA therapy in stroke patients is blood pressure (BP). Recent studies have found that DMF may impact BP. Both hypotension and hypertension need correction before treatment, which may delay the appropriate intervention. Since BP management is crucial in managing stroke patients, it is important to consider DMF's role in this matter. That being said, it seems further investigations on DMF may lead to an alternative approach for stroke patients. In this article, we discuss the mechanistic roles of DMF and its potential role in stroke based on previously published literature and laboratory findings.

Coexistence of neurofibromatosis type I, multiple sclerosis, and ischemic stroke: A case report and literature review

“… 32 On the other hand, dimethyl fumarate (DMF) is hypothesized to provide clinical benefit to MS patients in case of ischemic stroke. 33 …”

Biochemical and cellular basis of oxidative stress: Implications for disease onset

“…Moreover, BG-12 appears to suppress platelet function and thrombus formation (Chu et al, 2023). Several other reports suggest a potential ameliorative role for dimethyl fumarate in Alzheimer's disease, ischemic stroke, systemic lupus erythematosus, traumatic brain injury, among others (Cheng et al, 2023;Mauro et al, 2023;Owjfard et al, 2023). On the other hand, Oltipraz is currently in phase III trial for the treatment of nonalcoholic fatty liver disease (Robledinos-Antón et al, 2019) and is being proposed as potential agent for the management of Thoracic aortic aneurysm and dissection and osteoporosis (Wang et al, 2022;Yang et al, 2022).…”

Unveiling a foreign body masquerading as periarticular calcification: a case report

“…Seemingly minor details buried in a patient’s account may shed light on occult pathologies underlying their complaints. In cases of nonspecific limb discomfort, benign-appearing symptoms may signal retained foreign bodies or other occult disease processes [ 7 – 9 ].…”